Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Olanzapine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 7/20 | 0.98 |
| ▸ | HTR2A known ✓ | P28223 | 5/20 | 0.98 |
| ▸ | HTR2C known ✓ | P28335 | 5/20 | 0.98 |
| ▸ | DRD4 known ✓ | P21917 | 4/20 | 0.98 |
| ▸ | DRD3 known ✓ | P35462 | 3/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 10/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.98 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.98 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.98 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.98 |
| ▸ | DRD1 | P21728 | 5/20 | 0.98 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.98 |
| ▸ | HRH1 | P35367 | 5/20 | 0.98 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.98 |
| ▸ | HTR2B | P41595 | 5/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Olanzapine SCHEMBL5091769 | 1.00 | CHRM1 (0.98) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL1562676 | 1.00 | CHRM1 (0.98) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL1830363 | 0.99 | CHRM1 (0.95) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL16114506 | 0.99 | CHRM1 (0.95) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL28763 | 0.99 | CHRM1 (1.00) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL4775632 | 0.99 | CHRM1 (1.00) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL29358280 | 0.99 | CHRM1 (1.00) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL1376031 | 0.98 | CHRM1 (0.98) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL6461808 | 0.98 | CHRM1 (0.98) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL2222724 | 0.98 | CHRM1 (0.98) | CHRM1DRD2CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317849-A1 | Process For Producing Pure And Stable Form Of 2-Methyl-4-(4-Methyl-1-Piperazinyl) -10H-Thieno[2,3-B] [1,5] Benzodiazepine | JUBILANT ORGANOSYS LTD. (IN) | 2010-12-16 | — | — | US | claimed |
| EP-1994013-A4 | PROCESS FOR PRODUCING PURE AND STABLE FORM OF 2-METHYL-4-(4- METHYL- 1 -PIPERAZINYL)-10H-THIENO[2,3-b] [1,5]BENZODIAZEPINE | JUBILANT ORGANOSYS LTD (IN) | 2009-04-01 | — | — | EP | claimed |
| EP-1994013-A1 | PROCESS FOR PRODUCING PURE AND STABLE FORM OF 2-METHYL-4-(4- METHYL- 1 -PIPERAZINYL)-10H-THIENO[2,3-b] [1,5]BENZODIAZEPINE | Jubilant Organosys Limited (IN) | 2008-11-26 | — | — | EP | claimed |
| US-20080009481-A1 | Process For Making Form I Of Olanzapine | SHASUN CHEMICALS AND DRUGS LIMITED (IN) | 2008-01-10 | — | — | US | claimed |
| WO-2007105225-A1 | PROCESS FOR PRODUCING PURE AND STABLE FORM OF 2-METHYL-4-(4- METHYL- 1 -PIPERAZINYL)-10H-THIENO[2,3-b] [ 1,5]BENZODIAZEPINE | JUBILANT ORGANOSYS LIMITED (IN) | 2007-09-20 | — | — | WO | claimed |
| US-20070129352-A1 | Novel crystal forms, methods for their preparation and method for preparation of olanzapine | TEVA PHARMACEUTICAL INDUSTRIES LTD. | 2007-06-07 | — | — | US | claimed |
| EP-1781666-A1 | IMPROVED PROCESS FOR MAKING FORM I OF OLANZAPINE. | Shasun Chemicals and Drugs Limited (IN) | 2007-05-09 | — | — | EP | claimed |
| EP-1018880-A4 | 2-METHYL-THIENO-BENZODIAZEPINE FORMULATION | LILLY CO ELI (US) | 2006-06-14 | — | — | EP | claimed |
| CN-1239158-C | 2-methyl-thieno-benzodiazepine formulation | LILLY CO ELI (US) | 2006-02-01 | — | — | CN | claimed |
| WO-2006006185-A1 | IMPROVED PROCESS FOR MAKING FORM I OF OLANZAPINE. | SHASUN CHEMICALS AND DRUGS LIMITED (IN) | 2006-01-19 | — | — | WO | claimed |
| WO-2002018390-A1 | PROCESS FOR PREPARATION OF HYDRATES OF OLANZAPINE AND THEIR CONVERSION INTO CRYSTALLINE FORMS OF OLANZAPINE | DR. REDDY'S LABORATORIES LTD. (IN) | 2002-03-07 | — | — | WO | claimed |
| EP-0831098-B1 | Intermediates and process for preparing olanzapine | LILLY CO ELI (US) | 2001-11-21 | — | — | EP | claimed |
| US-6251895-B1 | STABLE CRYSTALLINE DIHYDRATE D OLANZAPINE POLYMORPH | ELI LILLY AND COMPANY | 2001-06-26 | — | — | US | claimed |
| CN-1271251-A | 2-methyl-thieno-benzodiazepine * formulations | LILLY CO ELI (US) | 2000-10-25 | — | — | CN | claimed |
| EP-1018880-A1 | 2-METHYL-THIENO-BENZODIAZEPINE FORMULATION | ELI LILLY AND COMPANY (US) | 2000-07-19 | — | — | EP | claimed |
| US-6020487-A | Intermediates and process for preparing olanzapine | ELI LILLY AND COMPANY (US) | 2000-02-01 | — | — | US | claimed |
| CN-1234802-A | Intermediates and process for preparing olanzapine | ELI LILLYAND CO (US) | 1999-11-10 | — | — | CN | claimed |
| WO-1999016313-A1 | 2-METHYL-THIENO-BENZODIAZEPINE FORMULATION | ELI LILLY AND COMPANY (US) | 1999-04-08 | — | — | WO | claimed |
| WO-1998012199-A1 | INTERMEDIATES AND PROCESS FOR PREPARING OLANZAPINE | ELI LILLY AND COMPANY (US) | 1998-03-26 | — | — | WO | claimed |
| EP-0831098-A2 | Intermediates and process for preparing olanzapine | ELI LILLY AND COMPANY (US) | 1998-03-25 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009481-A1 | Process For Making Form I Of Olanzapine | HTR1A, HTR1D, HTR1B | DRD2 26/4885HTR2A 21/4885HTR2C 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.